Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m², in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.

南韓與泰國肥胖（BMI ≥25 kg/m²）亞洲族群中，每週一次 semaglutide 2.4 mg 的療效（STEP 11）：一項隨機、雙盲、安慰劑對照、第三期臨床試驗